Patients with HR-positive, HER2-negative high-risk early breast cancer tended to experience improved invasive disease and distant relapse-free survival after adding Verzenio to endocrine therapy.
The oral, twice-daily tablet reduced the risk of long-term breast cancer recurrence by approximately 32%, and at 5 years, improved invasive disease-free survival by 7.6%.
Adding the CDK4/6 inhibitor to endocrine therapy among women with high-risk early breast cancer continues to show modest but clinically significant benefits 5 years in, compared with endocrine therapy alone.
Adjuvant treatment with the combination of abemaciclib and endocrine therapy (ET) maintained a benefit in invasive disease-free survival and distant relapse–free survival compared with ET alone in patients with hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer.